{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T19:34:04Z","timestamp":1767728044461,"version":"build-2238731810"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T00:00:00Z","timestamp":1473120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T00:00:00Z","timestamp":1473120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/pcan.2016.35","type":"journal-article","created":{"date-parts":[[2016,9,6]],"date-time":"2016-09-06T06:28:14Z","timestamp":1473143294000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients"],"prefix":"10.1038","volume":"19","author":[{"given":"C","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,6]]},"reference":[{"issue":"2 Suppl","key":"BFpcan201635_CR1","first-page":"49","volume":"25","author":"DF Paulson","year":"1985","unstructured":"Paulson DF . Management of metastatic prostatic cancer. Urology 1985; 25 (2 Suppl): 49\u201352.","journal-title":"Urology"},{"key":"BFpcan201635_CR2","first-page":"687","volume":"4","author":"LK Harle","year":"2006","unstructured":"Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S . Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 2006; 4: 687\u2013696.","journal-title":"Clin Adv Hematol Oncol"},{"key":"BFpcan201635_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","volume":"1","author":"S Magnan","year":"2015","unstructured":"Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E et al. Intermittent vs continuous androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis. JAMA Oncol 2015; 1: 1261\u20131269.","journal-title":"JAMA Oncol"},{"key":"BFpcan201635_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.eururo.2014.05.037","volume":"66","author":"L Boccon-Gibod","year":"2014","unstructured":"Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A et al. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur Urol 2014; 66: 655\u2013663.","journal-title":"Eur Urol"},{"key":"BFpcan201635_CR5","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FB, Hoffman KE, Hu JC, Parekh A et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 2011; 306: 2359\u20132366.","journal-title":"JAMA"},{"key":"BFpcan201635_CR6","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O'Malley AJ, Smith MR . Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448\u20134456.","journal-title":"J Clin Oncol"},{"key":"BFpcan201635_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493\u20131500.","journal-title":"Cancer"},{"key":"BFpcan201635_CR8","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR . Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516\u20131524.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201635_CR9","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","volume":"25","author":"AV D'Amico","year":"2007","unstructured":"D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420\u20132425.","journal-title":"J Clin Oncol"},{"key":"BFpcan201635_CR10","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1002\/cncr.23970","volume":"113","author":"AV D'Amico","year":"2008","unstructured":"D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW . Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 2008; 113: 3290\u20133297.","journal-title":"Cancer"},{"key":"BFpcan201635_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3322\/caac.20061","volume":"60","author":"GN Levine","year":"2010","unstructured":"Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010; 60: 194\u2013201.","journal-title":"CA Cancer J Clin"},{"key":"BFpcan201635_CR12","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314\u20131325.","journal-title":"N Engl J Med"},{"key":"BFpcan201635_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","volume":"55","author":"FE Calais da Silva","year":"2009","unstructured":"Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269\u20131277.","journal-title":"Eur Urol"},{"key":"BFpcan201635_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","volume":"63","author":"AJ Salonen","year":"2013","unstructured":"Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL . Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur Urol 2013; 63: 111\u2013120.","journal-title":"Eur Urol"},{"key":"BFpcan201635_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","volume":"66","author":"FCD Silva","year":"2014","unstructured":"Silva FCD, Silva F, Goncalves F, Santos A, Kliment J, Whelan P et al. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: Results from a randomised phase 3 study by the south european uroncological group. Eur Urol 2014; 66: 232\u2013239.","journal-title":"Eur Urol"},{"key":"BFpcan201635_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"365","author":"JM Crook","year":"2012","unstructured":"Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 365: 895\u2013903.","journal-title":"N Engl J Med"},{"key":"BFpcan201635_CR17","first-page":"720-7","volume":"69","author":"C Schulman","year":"2015","unstructured":"Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H et al. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study (ICELAND). Eur Urol 2015; 69: 720-7.","journal-title":"Eur Urol"},{"key":"BFpcan201635_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","volume":"2","author":"DL Hershman","year":"2015","unstructured":"Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic postate cancer. JAMA Oncol 2015; 2: 453\u2013461.","journal-title":"JAMA Oncol"},{"key":"BFpcan201635_CR19","unstructured":"Green JPHS . Cochrane Handbook for Systematic Reviews of Interventions, 2011."},{"key":"BFpcan201635_CR20","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815\u20132834.","journal-title":"Stat Med"},{"key":"BFpcan201635_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2490-14-9","volume":"14","author":"TE Botrel","year":"2014","unstructured":"Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol 2014; 14: 9.","journal-title":"BMC Urol"},{"key":"BFpcan201635_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG . Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557\u2013560.","journal-title":"BMJ"},{"key":"BFpcan201635_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177\u2013188.","journal-title":"Control Clin Trials"},{"key":"BFpcan201635_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1\u201334.","journal-title":"J Clin Epidemiol"},{"key":"BFpcan201635_CR25","first-page":"471","volume":"316","author":"F Song","year":"1998","unstructured":"Song F, Gilbody S . Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ 1998; 316: 471.","journal-title":"BMJ"},{"key":"BFpcan201635_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","volume":"14","author":"JL Mohler","year":"2016","unstructured":"Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA et al. Prostate cancer, Version 1, 2016. J Natl Compr Cancer Netw 2016; 14: 19\u201330.","journal-title":"J Natl Compr Cancer Netw"},{"key":"BFpcan201635_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467\u2013479.","journal-title":"Eur Urol"},{"key":"BFpcan201635_CR28","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.eururo.2013.04.020","volume":"64","author":"A Sciarra","year":"2013","unstructured":"Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013; 64: 722\u2013730.","journal-title":"Eur Urol"},{"key":"BFpcan201635_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","volume":"33","author":"S O'Farrell","year":"2015","unstructured":"O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M . Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2015; 33: 1243\u20131251.","journal-title":"J Clin Oncol"},{"key":"BFpcan201635_CR30","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829\u20131836.","journal-title":"JAMA"},{"key":"BFpcan201635_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/A:1020840311573","volume":"21","author":"MR Smith","year":"2002","unstructured":"Smith MR . Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 2002; 21: 159\u2013166.","journal-title":"Cancer Metastasis Rev"},{"key":"BFpcan201635_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0378-5122(01)00270-5","volume":"40","author":"A Cano","year":"2001","unstructured":"Cano A, Van Baal WM . The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas 2001; 40: 17\u201338.","journal-title":"Maturitas"},{"issue":"7_suppl","key":"BFpcan201635_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/jco.2015.33.7_suppl.151","volume":"33","author":"Celestia S. Higano","year":"2015","unstructured":"Higano CS, Crawford ED, Shore ND, Bosnyak Z, Malmberg A, Neijber A et al. Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: exploratory analysis of a randomized controlled trial. J Clin Oncol 2015; 33 (Suppl 7; Abstr 151).","journal-title":"Journal of Clinical Oncology"},{"key":"BFpcan201635_CR34","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1095\/biolreprod.102.012211","volume":"68","author":"VD Dixit","year":"2003","unstructured":"Dixit VD, Yang H, Udhayakumar V, Sridaran R . Gonadotropin-releasing hormone alters the T helper cytokine balance in the pregnant rat. Biol Reprod 2003; 68: 2215\u20132221.","journal-title":"Biol Reprod"},{"key":"BFpcan201635_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2249.2005.02904.x","volume":"142","author":"F Tanriverdi","year":"2005","unstructured":"Tanriverdi F, Gonzalez-Martinez D, Hu Y, Kelestimur F, Bouloux PM . GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005; 142: 103\u2013110.","journal-title":"Clin Exp Immunol"},{"key":"BFpcan201635_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.2001","volume":"12","author":"GK Hansson","year":"2011","unstructured":"Hansson GK, Hermansson A . The immune system in atherosclerosis. Nat Immunol 2011; 12: 204\u2013212.","journal-title":"Nat Immunol"}],"updated-by":[{"DOI":"10.1038\/pcan.2016.48","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201635.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201635","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201635.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T17:09:11Z","timestamp":1648660151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,6]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFpcan201635"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2016.35","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,6]]},"assertion":[{"value":"14 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}